AEON Biopharma, Inc.
AEON evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $16.3M
- Lead Asset:
- abp-450 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for AEON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AEON
AEON Biopharma, Inc. (AEON) is a biopharmaceutical company developing ABP-450, a biosimilar to BOTOX® (onabotulinumtoxinA), for therapeutic indications in the U.S., Canada, and the European Union.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$16.3M
Cash Runway
—
Lead Asset
abp-450 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for AEON Biopharma, Inc..
AEON Biopharma, Inc. (AEON) is a biopharmaceutical company developing ABP-450, a biosimilar to BOTOX® (onabotulinumtoxinA), for therapeutic indications in the U.S., Canada, and the European Union.
- AEON is advancing ABP-450, a botulinum toxin A biosimilar, for therapeutic indications including chronic migraine, cervical dystonia, and overactive bladder [pipeline].
- As of 2026-06-30, AEON reported cash & equivalents of $3.4M, net income of -$1.2M, and negative shareholders' equity of -$15.4M [sec].
- In August 2026, AEON executed a $15.3 million financing with milestone warrants that could provide an additional $34.0 million, extending cash runway into Q1 2027 [news · published 2026-08-12].
- FDA Type 2b meeting feedback (September 2026) clarified that prior head-to-head studies may be submitted as supportive evidence, and AEON plans to submit an IND for a CMAP pharmacodynamic study in Q4 2026 [news · published 2026-09-30].
- Analytical data show 100% amino acid identity and 98% sequence coverage of the active neurotoxin between ABP-450 and BOTOX®, with preserved disulfide bond architecture [news · published 2026-08-19].
What works
- AEON has received constructive FDA feedback (Type 2a and Type 2b meetings) that supports a potentially streamlined biosimilar development pathway for ABP-450 [news · published 2026-05-14][news · published 2026-09-30].
- Analytical comparability data, including forced degradation and structural characterization, demonstrate high molecular similarity between ABP-450 and BOTOX® [news · published 2026-09-09][news · published 2026-08-19].
- The company secured a $15.3 million financing with milestone-based warrants, providing cash runway into Q1 2027 to advance the ABP-450 program [news · published 2026-08-12].
What to weigh
- AEON's cash position is limited ($3.4M as of 2026-06-30) and shareholders' equity is deeply negative (-$15.4M), indicating a fragile financial position [sec].
- ABP-450 remains in preclinical development, with no IND submitted yet; the planned CMAP study is not expected to start until Q1 2027, so near-term revenue is absent [pipeline][news · published 2026-09-30].
- The biosimilar market for botulinum toxin A is competitive, with established products like Botox®, Dysport®, and Xeomin® already on the market [pipeline].
From the filings
Quoted directly from source documents.
Cash runway into Q1 2027
“Upfront proceeds from financing provide cash runway into the first quarter of 2027”
News · August 12, 2026
FDA feedback allows prior studies as supportive evidence
“FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence”
News · September 30, 2026
100% amino acid identity and 98% sequence coverage
“Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed”
News · August 19, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $3.4M as of 2026-06-30, with financing extending runway only into Q1 2027 [sec][news · published 2026-08-12].
- Preclinical stage, no IND yet — ABP-450 is preclinical; IND for CMAP study expected Q4 2026, study start Q1 2027 [pipeline][news · published 2026-09-30].
- Negative equity position — Shareholders' equity of -$15.4M as of 2026-06-30 indicates accumulated losses exceed assets [sec].
- Competitive market — Botox®, Dysport®, Xeomin® are established competitors in the botulinum toxin space [pipeline].
What to watch
- IND submission for the CMAP pharmacodynamic study, expected in Q4 2026 [news · published 2026-09-30].
- Initiation of the CMAP study in Q1 2027, which will provide key pharmacodynamic data [news · published 2026-09-30].
- Potential exercise of milestone warrants that could bring up to $34.0 million in additional financing [news · published 2026-08-12].
- Any further FDA guidance or updates on the biosimilar development pathway for ABP-450 [news · published 2026-09-30].
Sources: News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run AEON Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AEON Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$1M
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$2.8M
| Holder | Shares | Value |
|---|---|---|
| dauntless investment group, llc | 2,527,775 | $2.5M |
| vanguard capital management llc | 90,529 | $89K |
| geode capital management, llc | 87,062 | $86K |
| blue owl capital holdings lp | 42,353 | $42K |
| formidable asset management, llc | 20,024 | $22K |
| xtx topco ltd | 20,424 | $20K |
| jane street group, llc | 16,376 | $16K |
| vanguard fiduciary trust co | 14,702 | $14K |
| lpl financial llc | 11,507 | $11K |
| ubs group ag | 4,182 | $4K |
Showing top 10 of 24 institutional holders of AEON Biopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 0.6%
- Days to cover
- 2.1
- Shares short
- 144,810
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AEON short interestGovernance
Frequently asked questions
What is the AI investment thesis for AEON Biopharma, Inc.?
AEON Biopharma, Inc. (AEON) is a biopharmaceutical company developing ABP-450, a biosimilar to BOTOX® (onabotulinumtoxinA), for therapeutic indications in the U.S., Canada, and the European Union.
What is AEON Biopharma, Inc.'s lead drug candidate?
AEON Biopharma, Inc.'s most advanced tracked candidate is abp-450 (Preclinical) for Therapeutic indications for which Botox® is approved (including chronic migraine, cervical dystonia, blepharospasm, strabismus, overactive bladder, adult and pediatric detrusor overactivity, adult and pediatric upper and lower spasticity and axillary hyperhidrosis).
Who is the CEO of AEON Biopharma, Inc.?
Mr. Robert Bancroft is the chief executive officer of AEON Biopharma, Inc. (AEON).
Where is AEON Biopharma, Inc. headquartered?
AEON Biopharma, Inc. (AEON) is headquartered in Irvine, CA, United States.
What therapeutic areas does AEON Biopharma, Inc. focus on?
AEON Biopharma, Inc. develops therapies across Oncology, Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.